Recapitulation of the complete HDV replication cycle in a novel hepatoma cell line allows for efficient antiviral compound evaluation

Lempp, Florian A.; Schlund, Franziska; Rieble, Lisa; Nußbaum, Lea; Eck, C.; Ni, Yingchun; Urban, Stina L.

doi:10.1016/s0168-8278(18)31818-x

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These cell cultures have been successfully used to study hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. Mechanisms of HBV viral entry were discovered in HepRG cell lines (40), the expression/replication of HBV was discovered in HepG2 (41), and the complete HDV replication cell cycle was discovered in HepG2 and Huh7 cells (42,43). The shortcomings of these cell lines include significant changes in differentiation potential; altered genomic content (44); abnormal proteome expression; and the loss of features such as cellular polarity (45), contact inhibition (46,47), metabolic CYP450 potential (48,49), the induction of inflammatory mediators (50), as well as paracellular transport (51).…”

Section: Immortalized or Transformed Cell Linesmentioning

confidence: 99%

In Vitro Models of the Liver: Disease Modeling, Drug Discovery and Clinical Applications

Collins

Yuen

et al. 2019

Hepatocellular Carcinoma

View full text Add to dashboard Cite

In vitro models of the liver have led to important insights into the pathogenesis of liver disease. These models are essential tools in the discovery and preclinical stages of drug development. The clinical application of these models is also emerging as a promising avenue for validating genetic target-matched treatments, in a precision medicine approach to treatment. Recent advances in 'liver-on-a-chip' technology and liver organoid research have opened up new opportunities for the functional and clinical use of organotypic in vitro models. This chapter focuses on the currently available in vitro liver models and the opportunities and limitations they present in the context of evaluating their use in disease modeling, drug discovery, and clinical application.

show abstract

Section: Immortalized or Transformed Cell Linesmentioning

confidence: 99%

In Vitro Models of the Liver: Disease Modeling, Drug Discovery and Clinical Applications

Collins

Yuen

et al. 2019

Hepatocellular Carcinoma

View full text Add to dashboard Cite

show abstract

“…According to its mode of action Lonafarnib does not block intracellular HDV RNA replication, but results in an accumulation of HDAg and HDV replicative intermediates in vitro [97] (Lempp et al unpublished). The clinical consequences of this effect are presently unclear, but it might enhance the turnover rate of infected hepatocytes.…”

Section: Novel Treatment Options For Hdv Infected Patientsmentioning

confidence: 99%

Towards curative therapy of chronic viral hepatitis

2019

View full text Add to dashboard Cite

Persistent infection with hepatitis viruses is a major medical burden that unfortunately is often ignored in the general public. This results in a massive under-diagnosis of these infections. According to the world health organization, the number of people dying every year from the consequence of hepatitis virus infection has surpassed the death rate caused by malaria and HIV and is equivalent to the one of tuberculosis. These numbers call for more intense efforts to devise more effective, ideally curative therapies that must become as widely accessible as they are e. g. for HIV infected individuals. A major step forward has been the development of curative antiviral therapy for chronic hepatitis C. In the case of hepatitis D virus, new drug candidates have been developed that should receive conditional approval very soon. For chronic hepatitis B, development is lagging behind but thanks to a re-emerging interest of pharmaceutical industry that was triggered by the success of hepatitis C therapy and the availability of novel infection systems, new attempts towards curative approaches for this highly prevalent infection are undertaken. Here we summarize the current status of therapy development for chronic viral hepatitis that ultimately aims at cure.

show abstract

Recapitulation of the complete HDV replication cycle in a novel hepatoma cell line allows for efficient antiviral compound evaluation

Cited by 2 publications

References 0 publications

In Vitro Models of the Liver: Disease Modeling, Drug Discovery and Clinical Applications

In Vitro Models of the Liver: Disease Modeling, Drug Discovery and Clinical Applications

Towards curative therapy of chronic viral hepatitis

Contact Info

Product

Resources

About